Aquestive Therapeutics, Inc. Repayments of Debt
Aquestive Therapeutics, Inc. (AQST) reported Repayments of Debt of $45.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2026-08-11
- Aquestive Therapeutics, Inc. repayments of debt for the quarter ending 2026-06-30 was $44.99M.
- Aquestive Therapeutics, Inc. repayments of debt for the quarter ending 2026-03-31 was $8.00K, a 33.33% increase year-over-year.
- Aquestive Therapeutics, Inc. repayments of debt for the quarter ending 2025-06-30 was -$6.00K.
- Aquestive Therapeutics, Inc. repayments of debt for the quarter ending 2025-03-31 was $6.00K.
- Aquestive Therapeutics, Inc. repayments of debt for fiscal 2025 was $26.00K, a 13.04% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. repayments of debt for fiscal 2024 was $23.00K, a 99.96% decline from fiscal 2023.
- Aquestive Therapeutics, Inc. repayments of debt for fiscal 2023 was $51.53M.
- Aquestive Therapeutics, Inc. repayments of debt for fiscal 2022 was $0.00.
| Period end | Repayments of Debt 1 month | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $44.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $45.00M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $8.00K 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $26.00K 10-K · filed 2026-03-04 | ||||
| 2025-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | $6.00K 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | $23.00K 10-K · filed 2026-03-04 | ||||
| 2023-12-31 | $51.53M 10-K · filed 2025-03-05 | ||||
| 2023-03-31 | $9.09M 10-Q · filed 2023-05-02 | ||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-05 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-02 | ||||
| 2021-12-31 | $0.00 10-K · filed 2022-03-08 | ||||
| 2020-12-31 | $22.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $22.50M derived: sum of 2 quarters · filed 2022-03-08 | $22.50M 10-K · filed 2022-03-08 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $0.00 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-04 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $49.45M derived: sum of 2 quarters · filed 2021-03-09 | $50.00M 10-K · filed 2021-03-09 | ||
| 2019-09-30 | $49.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $50.00M 10-Q · filed 2020-11-04 | |||
| 2019-07-31 | $50.00M 10-K · filed 2020-03-11 | ||||
| 2019-06-30 | $550.00K 10-Q · filed 2020-08-04 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $0.00 derived: sum of 2 quarters · filed 2020-03-11 | $0.00 10-K · filed 2020-03-11 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |